Overexpression of glucose transporter 1 in esophageal squamous cell carcinomas: A marker for poor prognosis

Diseases of the Esophagus

Volumn 18, Issue 3, 2005, Pages 185-189

  Tohma, T ^a   Okazumi, S ^a   Makino, H ^a   Cho, A ^a   Mochizuki, R ^a   Shuto, K ^a   Kudo, H ^a   Matsubara, K ^a   Gunji, H ^a   Matsubara, H ^a   Ochiai, T ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Esophageal cancer; Glucose transporter; Poor prognosis

Indexed keywords

GLUCOSE TRANSPORTER 1; PARAFFIN;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 29144468939     PISSN: 11208694     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2005.00489.x     Document Type: Article

References (26)

1. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-14.
2. Pessin J E, Bell G I. Mammalian facilitative glucose transporter family: structure and molecular regulation. Ann Rev Physiol 1992; 54: 911-30.
3. Fleir J S, Mueckler M M, Usher P, Lodish H F. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987; 235: 1492-5.
4. Pardridge W, Boado R, Farrell C. Brain-type glucose transporter (GLUT1) is selectively localized to the blood-brain barrier. J Biol Chem 1990; 265: 18035-40.
5. Froehner S C, Davies A, Baldwin S A, Lienhard G E. The blood-nerve barrier is rich in glucose transporter. J Neurocytol 1988; 17: 173-8.
6. Younes M, Lechago L V, Lechago J. Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastasis. Clin Cancer Res 1996; 2: 1151-4.
7. Haber R S, Rathan A, Weiser K R et al. GLUT1 glucose transporter expression in colorectal carcinoma. Cancer 1998; 83: 34-40.
8. Furudoi A, Tanaka S, Hamura K et al. Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 2001; 60: 162-9.
9. Brown R S, Wahl R L. Overexpression of Glut-1 glucose transporter in human breast cancer. Cancer 1993; 72: 2979-85.
10. Younes M, Juarez D, Lechago L V, Lerner S P. Glut1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anticancer Res 2001; 21: 575-8.
11. Younes M, Brown R W, Stephenson M, Gondo M, Cagle P T. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997; 80: 1046-51.
12. Younes M, Ertan A, Lechago L V, Somoano J, Lechago J. Human erythrocyte glucose transporter (Glut1) is immunohistochemically detected as a late event during malignant progression in Barrett's metaplasia. Cancer Epidemiol 1997; 6: 303-5.
13. Younes M, Lechago J, Chakraborty S et al. Relationship between dysplasia, p53 protein accumulation, DNA ploidy, and Glut1 overexpression in Barrett metaplasia. Scand J Gastroenterol 2000; 35: 131-7.
14. Zimmerman R L, Burke M, Young N A, Solomides C C, Bibbo M. Diagnostic utility of Glut-1 and CA 15-3 in discriminating adenocarcinoma from hepatocellular carcinoma in liver tumors biopsied by fine-needle aspiration. Cancer 2002; 96: 53-7.
15. Higashi T, Tamaki N, Honda T et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med 1997; 38: 1337-44.
16. Reske S R, Grillenberger KG, Glatting G et al. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med 1997; 38: 1344-8.
17. Higashi T, Tamaki N, Torizuka T et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 1998; 39: 1727-35.
18. Musholt T J, Musholt P B, Dehdashti F, Moley J F. Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study. Surgery 1997; 122: 1049-61.
19. 18F-FDG uptake in non-small cell lung cancer. Eur J Nucl Med 2000; 27: 1778-85.
20. 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001; 42: 9-16.
21. Brown R S, Leung J Y, Kison P V, Zasadny K R, Flint A, Wahl R L. Glucose transporter and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 1999; 40: 556-65.
22. Smith TAD. FDG uptake, tumour characteristics and response to therapy: a new review. Nucl Med Commun 1998; 19: 97-105.
23. 18F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med 2002; 43: 173-80.
24. Union Internationale Contre le Cancer and the American Joint Committee on Cancer: TNM Classification of Malignant Tumors, fifth edition. Cancer 1997; 80: 1803-4.
25. Younes M, Pathak M, Finnie D, Sifers R N, Lin Y, Schwartz M R. Expression of the neutral amino acids transporter ASCT1 in esophageal carcinomas. Anticancer Res 2000; 20: 3775-9.
26. Kato H, Takita J, Miyazaki T et al. Glut-1 glucose transporter expression in esophageal squamous cell carcinoma is associated with tumor aggresiveness. Anticancer Res 2002; 22: 2635-40.